Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 103 of the 105 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and usually lethal disease of unknown aetiology. A growing body of evidence supports that IPF represents an epithelial-driven process characterised by aberrant epithelial cell behaviour, fibroblast/myofibroblast activation and excessive accumulation of extracellular matrix with the subsequent destruction of the lung architecture. The mechanisms involved in the abnormal hyper-activation of the epithelium are unclear, but we propose that recapitulation of pathways and processes critical to embryological development associated with a tissue specific age-related stochastic epigenetic drift may be implicated. These pathways may also contribute to the distinctive behaviour of IPF fibroblasts. Genomic and epigenomic studies have revealed that wingless/Int, sonic hedgehog and other developmental signalling pathways are reactivated and deregulated in IPF. Moreover, some of these pathways cross-talk with transforming growth factor-β activating a profibrotic feedback loop. The expression pattern of microRNAs is also dysregulated in IPF and exhibits a similar expression profile to embryonic lungs. In addition, senescence, a process usually associated with ageing, which occurs early in alveolar epithelial cells of IPF lungs, likely represents a conserved programmed developmental mechanism. Here, we review the major developmental pathways that get twisted in IPF, and discuss the connection with ageing and potential therapeutic approaches.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“cellular senescence has been linked to the pathogenesis of chronic lung diseases such as chronic obstructive pulmonary disease [14, 15] or IPF [16–20].”
From Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo (2017) · cites this paper as [20]
In the citing paper
“In addition to lung fibroblasts, evidence has emerged that alveolar epithelial cells can become senescent in IPF [16, 20, 24].”
From Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo (2017) · cites this paper as [20]
Citations
Cites
1 retracted
NF-κB activation impairs somatic cell reprogramming in ageing
Soria-Valles, C., Osorio, F. G., Gutiérrez-Fernández, A., De Los Angeles, A., Bueno, C., Menéndez, P., Martín-Subero, J. I., Daley, G. Q., Freije, J. M. P., & López-Otín, C. (2015) · Nature Cell Biology · doi:10.1038/ncb3207 · Cited by 95
Self-citationRetractedLópez-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
Self-citationEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Aging, Cellular Senescence, and Cancer
Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954
Cellular senescence: from physiology to pathology
Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationRaghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Self-citationClearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
Chang, J., Wang, Y., Shao, L., Laberge, R.-M., Demaria, M., Campisi, J., Janakiraman, K., Sharpless, N. E., Ding, S., Feng, W., et al. (2016) · Nature Medicine · doi:10.1038/nm.4010 · Cited by 1,819
Cited by
Martinez, F. J., Collard, H. R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., Swigris, J. J., Taniguchi, H., & Wells, A. U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.74 · Cited by 1,388
Self-citationEmerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
Mora, A. L., Rojas, M., Pardo, A., & Selman, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.170 · Cited by 402
Self-citationLehmann, M., Korfei, M., Mutze, K., Klee, S., Skronska-Wasek, W., Alsafadi, H. N., Ota, C., Costa, R., Schiller, H. B., Lindner, M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02367-2016 · Cited by 403
What's in a name? That which we call IPF, by any other name would act the same
Wells, A. U., Brown, K. K., Flaherty, K. R., Kolb, M., & Thannickal, V. J. (2018) · European Respiratory Journal · doi:10.1183/13993003.00692-2018 · Cited by 352
Epithelial–Mesenchymal Transition in the Pathogenesis of Idiopathic Pulmonary Fibrosis
Salton, F., Volpe, M., & Confalonieri, M. (2019) · Medicina · doi:10.3390/medicina55040083 · Cited by 261
“IPF prevalence is increasing worldwide and incidence increases with age, suggesting that senescence-related mechanisms could be major drivers in the pathogenesis of the disease [1,5,6].”
BackgroundMitochondria dysfunction and metabolic reprogramming as drivers of idiopathic pulmonary fibrosis
Bueno, M., Calyeca, J., Rojas, M., & Mora, A. L. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101509 · Cited by 275
“MicroRNAs expression can both promotes and attenuates fibrosis in a target-depended manner [115].”
BackgroundKatoh, M. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3689 · Cited by 211
“…to myocardial stiffness and ventricular dysfunction (32), whereas pulmonary fibrosis is caused by chronic inflammation associated with cancer therapy, cigarette smoking, connective tissue diseases, environmental pollution, infection, pulmonary hypertension and idiopathic pulmonary fibrosis (84,85).”
Therapeutic targets in lung tissue remodelling and fibrosis
Liu, G., Philp, A. M., Corte, T., Travis, M. A., Schilter, H., Hansbro, N. G., Burns, C. J., Eapen, M. S., Sohal, S. S., Burgess, J. K., et al. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107839 · Cited by 249
Mitochondria in the spotlight of aging and idiopathic pulmonary fibrosis
Mora, A. L., Bueno, M., & Rojas, M. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87440 · Cited by 235
The leading role of epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis
Selman, M., & Pardo, A. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109482 · Cited by 225
Self-citationPulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis
Meyer, K. C. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1312346 · Cited by 227
“(TGF-β) to activate and perpetuate profibrotic feedback loops [90,92].”
BackgroundLung cancer and interstitial lung disease: a literature review
Naccache, J.-M., Gibiot, Q., Monnet, I., Antoine, M., Wislez, M., Chouaid, C., & Cadranel, J. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.75 · Cited by 208
Luppi, F., Kalluri, M., Faverio, P., Kreuter, M., & Ferrara, G. (2021) · Respiratory Research · doi:10.1186/s12931-021-01711-1 · Cited by 194
“Senescent fibroblasts are mostly non-proliferative and show little evidence of apoptosis, which may contribute to their impaired elimination [28].”
BackgroundSelman, M., & Pardo, A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101393 · Cited by 211
“In addition, there are complex interactions and crosstalk between Wnt signaling and other pro-fibrotic pathways, such as Notch, RAS, TGF-β/Smad, and Hedgehog/Gli revealing the complexity of organ fibrosis (Hu et al., 2020a; Selman et al., 2016).”
BackgroundSelf-citationTime for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?
Wolters, P. J., Blackwell, T. S., Eickelberg, O., Loyd, J. E., Kaminski, N., Jenkins, G., Maher, T. M., Molina-Molina, M., Noble, P. W., Raghu, G., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30007-9 · Cited by 196
Self-citationInui, N., Sakai, S., & Kitagawa, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116107 · Cited by 169
ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis
Lagares, D., Ghassemi-Kakroodi, P., Tremblay, C., Santos, A., Probst, C. K., Franklin, A., Santos, D. M., Grasberger, P., Ahluwalia, N., Montesi, S. B., et al. (2017) · Nature Medicine · doi:10.1038/nm.4419 · Cited by 162
Self-citationHypersensitivity Pneumonitis: Current Concepts of Pathogenesis and Potential Targets for Treatment
Vasakova, M., Selman, M., Morell, F., Sterclova, M., Molina-Molina, M., & Raghu, G. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201903-0541pp · Cited by 161
“As mentioned, aging may play a role in fibroproliferative response in HP either in mice model or in real-world patients as well; mouse models have demonstrated that response to inhalation antigens differ in young and old animals, and, in human fibrosing HP, is mostly diagnosed in elder patients (48, 49).”
BackgroundSelf-citationInflammation and Wnt Signaling: Target for Immunomodulatory Therapy?
Jridi, I., Canté-Barrett, K., Pike‐Overzet, K., & Staal, F. J. T. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.615131 · Cited by 170
“Pulmonary fibrosis results from the development and the progression of chronic inflammation associated with infection, air pollution, cigarette smoking, and cancer therapy (Selman et al., 2016).”
BackgroundDrug nanodelivery systems based on natural polysaccharides against different diseases
Rehman, A., Jafari, S. M., Tong, Q., Riaz, T., Assadpour, E., Aadil, R. M., Niazi, S., Khan, I. M., Shehzad, Q., Ali, A., et al. (2020) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2020.102251 · Cited by 157
Chronic WNT/β-catenin signaling induces cellular senescence in lung epithelial cells
Lehmann, M., Hu, Q., Hu, Y., Hafner, K., Costa, R., van den Berg, A., & Königshoff, M. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109588 · Cited by 147
Erratum: Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
Mora, A. L., Rojas, M., Pardo, A., & Selman, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.225 · Cited by 128
Self-citationPardo, A., & Selman, M. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0373ps · Cited by 117
Self-citationSenotherapeutics: targeting senescence in idiopathic pulmonary fibrosis
Merkt, W., Bueno, M., Mora, A. L., & Lagares, D. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.12.008 · Cited by 119
Integrative analysis of cell state changes in lung fibrosis with peripheral protein biomarkers
Mayr, C. H., Simon, L. M., Leuschner, G., Ansari, M., Schniering, J., Geyer, P. E., Angelidis, I., Strunz, M., Singh, P., Kneidinger, N., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012871 · Cited by 106
The Aging Lung and Idiopathic Pulmonary Fibrosis
Gulati, S., & Thannickal, V. J. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.02.008 · Cited by 111
Selman, M., & Pardo, A. (2021) · European Respiratory Journal · doi:10.1183/13993003.04507-2020 · Cited by 88
Self-citationPotential contribution of alveolar epithelial type I cells to pulmonary fibrosis
Kasper, M., & Barth, K. (2017) · Bioscience Reports · doi:10.1042/bsr20171301 · Cited by 88
Genetics of idiopathic pulmonary fibrosis: from mechanistic pathways to personalised medicine
Spagnolo, P., & Cottin, V. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-103973 · Cited by 82
Renzoni, E. A., Poletti, V. E., & Mackintosh, J. A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01961-9 · Cited by 76
WNT Signaling in Lung Aging and Disease
Lehmann, M., Baarsma, H. A., & Königshoff, M. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201608-586aw · Cited by 73
Cellular Senescence in Idiopathic Pulmonary Fibrosis
Kellogg, D. L., Kellogg, D. L., Musi, N., & Nambiar, A. M. (2021) · Current Molecular Biology Reports · doi:10.1007/s40610-021-00145-4 · Cited by 67
Moimas, S., Salton, F., Kośmider, B., Ring, N., Volpe, M. C., Bahmed, K., Braga, L., Rehman, M., Vodret, S., Graziani, M. L., et al. (2019) · ERJ Open Research · doi:10.1183/23120541.00138-2019 · Cited by 66
Chaotic activation of developmental signalling pathways drives idiopathic pulmonary fibrosis
Froidure, A., Marchal-Duval, E., Homps-Legrand, M., Ghanem, M., Justet, A., Crestani, B., & Mailleux, A. (2020) · European Respiratory Review · doi:10.1183/16000617.0140-2019 · Cited by 55
The Hedgehog Signaling Pathway in Idiopathic Pulmonary Fibrosis: Resurrection Time
Effendi, W. I., & Nagano, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010171 · Cited by 59
“Repetitive and subclinical epithelial injury that has been superimposed onto accelerated epithelial aging, host defense abnormalities, and the dysbiosis of microbiome induce aberrant wound healing and deposition of ECM through the myofibroblasts [77].”
BackgroundInfluentialEmerging insights into the role of matrix metalloproteases as therapeutic targets in fibrosis
Afratis, N. A., Selman, M., Pardo, A., & Sagi, I. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.02.007 · Cited by 61
Self-citationImpact of Transcriptomics on Our Understanding of Pulmonary Fibrosis
Vukmirovic, M., & Kaminski, N. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00087 · Cited by 64
“While the cellular origin and exact effects of all of these common microRNA changes are unclear, together with the observations about lung development, microRNA changes in the IPF lung suggest a loss of the differentiated organ regulatory networks potentially as a result of desynchronized aging (102, 103).”
BackgroundPredictive factors and prognostic effect of telomere shortening in pulmonary fibrosis
Planas‐Cerezales, L., Arias‐Salgado, E. G., Buendía-Roldán, I., Montes‐Worboys, A., Esquinas, C., Vicens‐Zygmunt, V., Hernaiz, P. L., Sanuy, R. L., Leiro‐Fernández, V., Balcells, E., et al. (2018) · Respirology · doi:10.1111/resp.13423 · Cited by 62
Self-citationTirelli, C., Pesenti, C., Miozzo, M. R., Mondoni, M., Fontana, L., & Centanni, S. (2022) · Diagnostics · doi:10.3390/diagnostics12123107 · Cited by 57
“Other emerging pathways involved in the development of the lung, and which seem to be epigenetically influenced in IPF patients are the Hedgehog pathway GLI1 and the WNT pathway of beta-catenin [105].”
BackgroundDelayed resolution of bleomycin-induced pulmonary fibrosis in absence of MMP13 (collagenase 3)
Cabrera, S., Maciel, M., Hernández-Barrientos, D., Calyeca, J., Gaxiola, M., Selman, M., & Pardo, A. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00455.2017 · Cited by 55
Self-citationLee, J. S., La, J. L., Aziz, S., Dobrinskikh, E., Brownell, R., Jones, K. D., Achtar‐Zadeh, N., Green, G., Elicker, B. M., Golden, J. A., et al. (2021) · Histopathology · doi:10.1111/his.14334 · Cited by 58
“Studies have shown that molecular changes commonly associated with ageing are found in IPF patients.(3) Consistent with molecular ageing contributing to the pathogenesis of IPF, IPF patients have short telomeres(4,5) and express markers of senescence (p16, p21, and p53) in alveolar type II (AECII) cells,(6,7) where th…”
BackgroundPlasma membrane wounding and repair in pulmonary diseases
Cong, X., Hubmayr, R. D., Li, C., & Zhao, X. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00486.2016 · Cited by 48
Lipids - two sides of the same coin in lung fibrosis
Mamazhakypov, A., SCHERMULY, R. T., Schaefer, L., & Wygrecka, M. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.04.007 · Cited by 47
Wang, L., Zhu, M., Li, Y., Yan, P., Li, Z., Chen, X., Yang, J., Pan, X., Zhao, H., Wang, S., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100524 · Cited by 49
McErlean, P. K., Bell, C. G., Hewitt, R. J., Busharat, Z., Ogger, P. P., Ghai, P., Albers, G. J., Calamita, E., Kingston, S., Molyneaux, P. L., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202101-0004oc · Cited by 48
“Advanced age is a key risk factor for IPF(44), and numerous studies have shown that molecular changes commonly associated with aging such as telomere shortening (45, 46) and augmented markers of senescence (47, 48) are found in IPF patients.”
BackgroundAntineutrophil Cytoplasmic Antibody–Associated Lung Fibrosis
Borie, R., & Crestani, B. (2018) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0038-1669914 · Cited by 46
Regenerative pharmacology for COPD: breathing new life into old lungs
Ng-Blichfeldt, J.-P., Gosens, R., Dean, C. H., Griffiths, M., & Hind, M. D. (2019) · Thorax · doi:10.1136/thoraxjnl-2018-212630 · Cited by 46
“108 Development of therapeutics with well-defined clearance or degradation pathways, and thorough characterisation of in vivo pharmacokinetics in human subjects, will aid in fine tuning key signalling pathways for therapeutic applications.”
Gerckens, M., Schorpp, K., Pelizza, F., Wögrath, M., Reichau, K., Ma, H., Dworsky, A.-M., Sengupta, A., Stoleriu, M. G., Heinzelmann, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb3673 · Cited by 37
“In fibrotic pathogenesis, repetitive and constant injury leads to a sustained and self-perpetuating activation of fibroblasts, leading to their transdifferentiation into synthetic and highly contractile – smooth muscle actin (SMA)–expressing myofibroblasts that massively deposit extracellular matrix (ECM), which sti…”
BackgroundReal-life prevalence of progressive fibrosing interstitial lung diseases
Gagliardi, M., Berg, D. V., Heylen, C. E., Koenig, S., Hoton, D., Tamirou, F., Pieters, T., Ghaye, B., & Froidure, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-03481-8 · Cited by 43
van Batenburg, A. A., Kazemier, K. M., van Oosterhout, M. F. M., van der Vis, J. J., Grutters, J. C., Goldschmeding, R., & van Moorsel, C. H. M. (2021) · ERJ Open Research · doi:10.1183/23120541.00691-2020 · Cited by 40
Selman, M., Martinez, F. J., & Pardo, A. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201806-1166pp · Cited by 35
Self-citationPan, X., Wang, L., Yang, J., Li, Y., Xu, M., Liang, C., Liu, L., Li, Z., Xia, C., Pang, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52827-z · Cited by 38
Huang, Q., Chen, Y., Shen, S., Wang, Y., Liu, L., Wu, S., Xu, W. D., Zhao, W., Lin, M., & Wu, J. (2020) · Aging · doi:10.18632/aging.102978 · Cited by 34
“As a quintessential aging-related lung disease [5, 6], IPF occurs in middle-aged and elderly adults [7] and its prevalence rises remarkably with age [8].”
BackgroundNovella-Navarro, M., & Balsa, A. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00976-5 · Cited by 35
LncRNA PFAR contributes to fibrogenesis in lung fibroblasts through competitively binding to miR-15a
Sun, J., Su, W., Zhao, X., Shan, T., Jin, T., Guo, Y., Li, C. R., Li, R., Zhou, Y., Shan, H., et al. (2019) · Bioscience Reports · doi:10.1042/bsr20190280 · Cited by 32
Yuan, J., Li, P., Pan, H., Xu, Q., Xu, T., Li, Y., Wei, D., Mo, Y., Zhang, Q., Chen, J., et al. (2021) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2021.112372 · Cited by 32
Interstitial Lung Disease in Elderly Rheumatoid Arthritis Patients
Messina, R., Guggino, G., Benfante, A., & Scichilone, N. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00727-z · Cited by 31
Rackow, A. R., Nagel, D. J., McCarthy, C., Judge, J., Lacy, S. H., Freeberg, M. A. T., Thatcher, T. H., Kottmann, R. M., & Sime, P. J. (2020) · European Respiratory Journal · doi:10.1183/13993003.00075-2020 · Cited by 31
“This process is implicated in the pathogenesis of lung scarring [29, 48, 49], because IPF is a disease of aged individuals.”
BackgroundUpregulation and Nuclear Location of MMP28 in Alveolar Epithelium of Idiopathic Pulmonary Fibrosis
Maldonado, M., Salgado-Aguayo, A. R., Herrera, I., Cabrera, S., Ortíz-Quintero, B., Staab-Weijnitz, C. A., Eickelberg, O., Ramírez, R., Manicone, A. M., Selman, M., et al. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0223oc · Cited by 30
“In turn, hyperactivated alveolar epithelial cells (AECs) produce numerous mediators, which result in an increase of the fibroblast/myofibroblast population, excessive accumulation of extracellular matrix (ECM), and the destruction of lung architecture (1, 2, 5, 6).”
BackgroundSelf-citationp16-3MR: A Novel Model to Study Cellular Senescence in Cigarette Smoke-Induced Lung Injuries
Kaur, G., Sundar, I. K., & Rahman, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094834 · Cited by 29
Zhang, Y., Jones, K. D., Achtar‐Zadeh, N., Green, G., Kukreja, J., Xu, B., & Wolters, P. J. (2019) · Histopathology · doi:10.1111/his.13745 · Cited by 26
“Pirfenidone and nintedanib, referred to colloquially as ‘antifibrotic medications’, have recently been approved for treatment of IPF.”
BackgroundInfluentialR-Spondin-2 Is Upregulated in Idiopathic Pulmonary Fibrosis and Affects Fibroblast Behavior
Munguía-Reyes, A., Balderas-Martínez, Y. I., Becerril, C., Checa, M., Ramírez, R., Ortiz, B., Meléndez-Zajgla, J., Pardo, A., & Selman, M. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0115oc · Cited by 24
“The pathogenic mechanisms remain incompletely understood, but recent evidence suggests that the recapitulation of developmental pathways may play a role (3, 4).”
BackgroundSelf-citationOrtíz-Quintero, B., Buendía-Roldán, I., Ramírez-Salazar, E. G., Balderas-Martínez, Y. I., Ramírez-Rodriguez, S. L., Martínez‐Espinosa, K., & Selman, M. (2020) · Cells · doi:10.3390/cells9061556 · Cited by 23
“In particular, transforming growth factor beta (TGF-β) signaling pathway (miR-200c-3p, miR-16-5p, miR-21-5p and miR-34-5p) and Wnt signaling pathway (miR-200c-3p, miR-16-5p and miR-34-5p) are known pathways directly associated to IPF and lung fibrosis in literature [38,39].”
BackgroundSelf-citationMaciel, M., Hernández-Barrientos, D., Herrera, I., Selman, M., Pardo, A., & Cabrera, S. (2018) · Aging · doi:10.18632/aging.101532 · Cited by 22
“Several lines of evidence support that apoptosis of epithelial cells is a key event initiating and promoting pulmonary fibrosis [1-3].”
BackgroundSelf-citationNicotinamide mononucleotide ameliorates senescence in alveolar epithelial cells
Fang, T., Yang, H. J., Liu, L., Xiao, H., & Wei, X. (2021) · MedComm · doi:10.1002/mco2.62 · Cited by 22
Exosomal Micro-RNAs as Intercellular Communicators in Idiopathic Pulmonary Fibrosis
Negrete-García, M. C., Ramos-Abundis, J. D. J., Alvarado‐Vásquez, N., Montes-Martínez, E., Montaño, M., Ramos, C., & Sommer, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911047 · Cited by 22
“It is well known that in degenerative chronic pulmonary diseases, a response is generated by the resident progenitor cell populations to promote the regeneration and repair of tissue damage [113,114].”
BackgroundShao, M., Qiu, Y., Shen, M., Liu, W. Q., Feng, D., Luo, Z., & Zhou, Y. (2024) · The FASEB Journal · doi:10.1096/fj.202302547rr · Cited by 27
“12 Cellular senescence, a hallmark of aging, is driven by several factors, including telomere attrition, oxidative stress, DNA damage, and stress-induced cell cycle arrest.”
Increased circulating desmosine and age-dependent elastinolysis in idiopathic pulmonary fibrosis
de Brouwer, B., Drent, M., van den Ouweland, J. M. W., Wijnen, P. A. H. M., van Moorsel, C. H. M., Bekers, O., Grutters, J. C., White, E. S., & Janssen, R. (2018) · Respiratory Research · doi:10.1186/s12931-018-0747-6 · Cited by 20
“We now demonstrate that agerelated pDES increment is also amplified in IPF, which corroborates to the acceleration of ageing processes observed in patients with IPF [11].”
ResultLicence to kill senescent cells in idiopathic pulmonary fibrosis?
Mailleux, A., & Crestani, B. (2017) · European Respiratory Journal · doi:10.1183/13993003.01360-2017 · Cited by 21
Most Promising Emerging Therapies for Pulmonary Fibrosis: Targeting Novel Pathways
Carriera, L., Lipsi, R., Dodaj, M., Inchingolo, R., Smargiassi, A., Coppola, A., Mari, P., Barone, R., Ielo, S., Scala, R., et al. (2026) · Biomedicines · doi:10.3390/biomedicines14010154 · Cited by 20
“In pulmonary fibrosis, Hh signaling becomes aberrantly reactivated and dysregulated [91].”
Emerging roles of non-coding RNAs in fibroblast to myofibroblast transition and fibrotic diseases
Xing, X., & Rodeo, S. A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1423045 · Cited by 18
A novel prognostic signature for idiopathic pulmonary fibrosis based on five-immune-related genes
Qiu, L., Gong, G., Wu, W., Li, N., Li, Z., Chen, S., Li, P., Chen, T., Zhao, H., Hu, C., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4545 · Cited by 19
“The pathophysiological pathogenesis of IPF involves aberrant transcription and gene expression (9-14).”
BackgroundSala, M. A., Balderas-Martínez, Y. I., Buendía-Roldán, I., Abdala‐Valencia, H., Nam, K.-W., Jain, M., Bhorade, S. M., Bharat, A., Reyfman, P. A., Ridge, K. M., et al. (2018) · Respiratory Research · doi:10.1186/s12931-018-0932-7 · Cited by 18
Self-citationRecent Advances in Senolysis for Age-Related Diseases
Aratani, S., & Nakanishi, M. (2023) · Physiology · doi:10.1152/physiol.00003.2023 · Cited by 19
Spannbrucker, T., Ale‐Agha, N., Goy, C., Dyballa‐Rukes, N., Jakobs, P., Jander, K., Altschmied, J., Unfried, K., & Haendeler, J. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2018.11.017 · Cited by 16
“In IPF, senescence-associated changes in cellular signalling of epithelial cells appear to be involved in processes like epithelial to mesenchymal transition and tissue remodelling (Selman et al., 2016).”
Yao, L., Xu, Z., Davies, D. E., Jones, M. G., & Wang, Y. (2024) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2024.02.001 · Cited by 16
“39 Furthermore, some of the secreted regulators are coagulation related, such as tissue factor/factor VIIa/factor X (TF/FVIIa/FX) complex, protease-activated receptor 1 and 2, and plasminogen activator inhibitor-1 (PAI-1).”
Shakeel, I., Afzal, M., Islam, A., Sohal, S. S., & Hassan, M. I. (2023) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2023.100167 · Cited by 16
Falcón, V., González, T. M., Acosta-Medina, E. F., Guillén, G. E., Berlanga‐Acosta, J., Fernández‐Ortega, C., Alfonso-Falcón, A., Gilva-Rodríguez, N., López-Nocedo, L., Cremata-García, D., et al. (2023) · Archives of Virology · doi:10.1007/s00705-023-05711-y · Cited by 16
Zhang, Y., Zhou, L., Cheng, G., Zhou, Y., Guo, Q., Wu, J., Wong, Y. K., Zhang, J., Tang, H., & Wang, J. (2024) · MedComm – Future Medicine · doi:10.1002/mef2.91 · Cited by 12
Romero, Y., Balderas-Martínez, Y. I., Vargas-Morales, M. A., Castillejos-López, M. D. J., Vázquez-Pérez, J. A., Calyeca, J., Espíndola, L. M. T., Patiño, N., Camarena, Á., Carlos‐Reyes, Á., et al. (2022) · Cells · doi:10.3390/cells11193014 · Cited by 11
Luo, M., Al-waqeerah, A., & Gao, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1742761 · Cited by 10
The role of heat shock protein 90 in idiopathic pulmonary fibrosis: state of the art
Monteleone, G., Cameli, P., & Bonella, F. (2025) · European Respiratory Review · doi:10.1183/16000617.0147-2024 · Cited by 10
“In IPF, the increased expression of miR-154 and the reduced expression of miR-30a, miR-30d and miR-92a are likely to induce the Wnt/ β -catenin pro-fibrotic pathway [49].”
InfluentialYang, Z., Wang, M., Ren, Y., Li, L., Cao, L., Zhang, W., Lv, K., Sun, Z., & Nie, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120027 · Cited by 10
Monteleone, G., Passantino, L., Simonetti, J., Iovene, B., Varone, F., Cameli, P., Sgalla, G., & Richeldi, L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145100 · Cited by 9
“Amid these, the increased expression of miR-154, which inhibits Wnt/beta-catenin profibro-genic pathway suppressors, and the reduced expression of miR-30a, miR-30d and miR-92a appeared to target developmental pathways and promote fibrosis development [13].”
InfluentialJiang, Y., Wang, Z., Hu, J., Wang, W., Zhang, N., & Gao, L. (2023) · Aging · doi:10.18632/aging.205036 · Cited by 9
Calyeca, J., Balderas-Martínez, Y. I., Olmos, R., Jasso, R., Maldonado, V., Rivera, Q., Selman, M., & Pardo, A. (2018) · Aging · doi:10.18632/aging.101679 · Cited by 10
“Although the pathogenic mechanisms are uncertain, most evidence indicates that IPF results from the hyperactivation of the respiratory epithelium, which secretes a variety of mediators that induce the migration, proliferation, and activation of fibroblasts with the subsequent destruction of the lung parenchyma [2-4, 5…”
BackgroundSelf-citationJankowski, K., Lemay, S.-E. S., Lozano‐Ojalvo, D., Pérez‐Rodríguez, L., Sauvaget, M., Breuils‐Bonnet, S., Formoso, K., Jagana, V., Ochoa, M. T., Zhang, S., et al. (2025) · European Respiratory Journal · doi:10.1183/13993003.02250-2024 · Cited by 9
Diken, Ö. E., Güngör, Ö., & Akkaya, H. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03226-z · Cited by 8
“The pathophysiology and mechanisms of the increase in IPF cases in older adults have been investigated [14, 15].”
BackgroundA recurring theme in pulmonary fibrosis genetics
Wolters, P. J. (2017) · European Respiratory Journal · doi:10.1183/13993003.00545-2017 · Cited by 8
Aging Delays Lung Repair: Insights from Omics Analysis in Mice with Pulmonary Fibrosis
Liang, J., & Ligresti, G. (2023) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2023-0171ed · Cited by 8
“The identi fi cation of the endodermal cell differentiation signaling in fi brosis resolution in old mice reinforces the notion that aberrant recapitulation of major lung developmental pathways, such as WNT, Notch, and TGF-b , may contribute to the pathogenesis of IPF (11, 12).”
Histologic Analysis of Idiopathic Pulmonary Fibrosis by Morphometric and Fractal Analysis
Mancini, M., Bargiacchi, L., Vitis, C. D., D’Ascanio, M., Dominicis, C. D., Ibrahim, M., Rendina, E. A., Rícci, A., Napoli, A. D., Mancini, R., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11051483 · Cited by 7
Fibroblast Senescence and Apoptosis. “One-Two Punch” to Slow Down Lung Fibrosis?
Pardo, A., & Selman, M. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0387ed · Cited by 7
Self-citationJeries, H., Daood, R., Hijazi, B., Golan‐Cohen, A., Green, I., Merzon, E., Naffaa, M. E., & Hassan, F. (2024) · Musculoskeletal Care · doi:10.1002/msc.1928 · Cited by 6
PAI-1 Derived from Alveolar Type 2 Cells Drives Aging-Associated Pulmonary Fibrosis
Quan, R., Shi, C., Sun, Y., Zhang, C., Bi, R., Zhang, Y., Bi, X., Liu, B., Dong, Z., Jin, D., et al. (2024) · Engineering · doi:10.1016/j.eng.2024.08.014 · Cited by 6
Chilosi, M., Piciucchi, S., Ravaglia, C., Spagnolo, P., Sverzellati, N., Tomassetti, S., Wuyts, W. A., & Poletti, V. E. (2024) · Pulmonology · doi:10.1016/j.pulmoe.2024.05.005 · Cited by 6
Cerri, S., Manzini, E., Nori, O., Pacchetti, L., Rossi, L., Turchiano, M. G., Samarelli, A. V., Raineri, G., Andrisani, D., Gozzi, F., et al. (2024) · Medicina · doi:10.3390/medicina60121967 · Cited by 7
“Although the exact mechanisms driving ILD pathogenesis remain unclear, there is growing evidence that telomere shortening and genetic instability—hallmarks of early cellular aging—play a key role in the fibrotic process [22,23].”
Epithelial stem cells at the intersection of tissue regeneration and pulmonary fibrosis
Platé, M., Kobayashi, Y., Chambers, R. C., & Tata, P. R. (2021) · European Respiratory Society eBooks · doi:10.1183/2312508x.10010420 · Cited by 6
Kim, Y. B., Yoon, Y.-S., Choi, Y. J., Park, E., & Kang, J. L. (2017) · Oncotarget · doi:10.18632/oncotarget.22737 · Cited by 6
“Although the pathogenic mechanisms leading to IPF have not been fully elucidated, dysregulation of apoptosis and ageing appears to be the major driving forces [2, 3].”
BackgroundResearch in Pulmonary Fibrosis Across Species: Unleashing Discovery Through Comparative Biology
Barnes, T. R., Brown, K. K., CORCORAN, B. M., Glassberg, M. K., Kervitsky, D. J., LIMPER, A. H., McGuire, K., Williams, K. J., & Roman, J. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.02.005 · Cited by 6
“New data regarding the potential role of oxidative stress, dysregulated miRNAs, epigenetics, telomere shortening, tissue stiffness, aberrant metabolism, altered immunity, and aging have further added depth to our understanding of mechanisms of disease, but it is too early to determine if this new knowledge will lead t…”
BackgroundAI-driven toolset for IPF and aging research associates lung fibrosis with accelerated aging
Galkin, F., Chen, S., Aliper, A. M., Zhavoronkov, A. A., & Ren, F. (2025) · Aging · doi:10.18632/aging.206295 · Cited by 8
Metadata
- Authors
- Selman, M., López-Otín, C., & Pardo, A.
- Affiliations
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Universidad Nacional Autónoma de México (MX)
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2016-07-07
- Volume
- 48
- Issue
- 2
- Pages
- 538-552
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2465575280
- Cited by
- 122
- References
- 105
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 11 · 2023: 8 · 2022: 6 · 2021: 24 · 2020: 10 · 2019: 14 · 2018: 19 · 2017: 13 · 2016: 2
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-nd
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- Consultation of the Doctoral Thesis Database (TESEO) (Ministerio de Educación, Cultura y Deporte) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, alveolar epithelial cells, fibroblast activation, myofibroblasts, extracellular matrix accumulation, Sonic hedgehog signaling, TGF-beta, microRNA dysregulation, cellular senescence, aging, treatment options
- MeSH terms
- Aged, Aging, Animals, Fibroblasts, Humans, Lung, Stochastic Processes, Transcription, Genetic, Signal Transduction, MicroRNAs, Genetic Drift, Epigenesis, Genetic, Mice, Idiopathic Pulmonary Fibrosis, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.